口服麦醇溶蛋白保护超氧化物歧化酶联合光疗治疗非节段性白癜风:24周前瞻性随机安慰剂对照研究
该24周单中心前瞻性随机安慰剂对照试验纳入50例非节段性白癜风患者,评估口服麦醇溶蛋白保护超氧化物歧化酶(GP-SOD)联合NB-UVB的疗效。结果显示GP-SOD组VES改善19.85%(SE 4.63, P<0.0001),安慰剂组改善8.83%(SE 4.72, P=0.0676),两组耐受性良好,无相关副作用。
要点
- GP-SOD联合NB-UVB较安慰剂联合NB-UVB显著改善VES评分
- GP-SOD组VES改善19.85%(SE 4.63, P<0.0001),安慰剂组8.83%(SE 4.72, P=0.0676)
- 两组耐受性良好,未报告相关副作用
核心结论
- GP-SOD联合NB-UVB似乎是非节段性白癜风治疗中有用的辅助手段。
研究设计与样本
- 24周单中心干预性前瞻性随机安慰剂对照试验,在法国尼斯大学医院皮肤科白癜风三级中心进行。
- 共纳入50例影响超过5%总体表面积的非节段性白癜风患者。
- 受试者接受GP-SOD(1 g/天12周后0.5 g/天12周)或安慰剂,联合每周两次NB-UVB。
- 主要终点为24周时通过标准化照片上研究者评估的VES评分与基线比较的总复色率。
主要发现
- 24周后,GP-SOD组VES改善19.85%(SE 4.63, P<0.0001),安慰剂组改善8.83%(SE 4.72, P=0.0676)。
- 两组耐受性良好,未报告相关副作用。
临床怎么用
- GP-SOD可作为光疗的辅助治疗用于非节段性白癜风患者。
- 需注意该研究为单中心小样本试验,结果需进一步验证。
局限性
- 研究为单中心设计,样本量50例。
- 安慰剂组VES改善P=0.0676未达统计学显著性,可能影响组间比较解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract. OBJECTIVE: To evaluate the efficacy of gliadin-protected SOD (GP-SOD), associated with narrowband ultraviolet B(NB-UVB), for treating vitiligo. METHODS: We conducted a 24-week monocentric interventional prospective randomized placebo-controlled trial in the tertiary center for vitiligo care in the department of Dermatology of Nice University hospital, Nice, France. Subjects with non-segmental vitiligo affecting more than 5% of the total body surface were included. The subjects received gliadin-protected SOD (GP-SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) or placebo in combination with twice-weekly sessions of NB-UVB. The primary endpoint was the total repigmentation rate at 24 weeks, compared with baseline, as assessed by investigator-assessed Vitiligo Extent Score (VES) on standardized pictures. RESULTS: A total of 50 patients were included. After 24 weeks, a greater improvement in VES was observed in the GP-SOD group (19.85%; SE 4.63, P < 0.0001) compared with the placebo group (8.83%; SE 4.72, P = 0.0676). Tolerance was good in both groups. No related side-effect was reported. CONCLUSIONS: The use of GP-SOD appears to be a useful add-on to phototherapy in the treatment of vitiligo patients.
引用
- Fontas E, Montaudié H, Passeron T, et al. Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: A 24-week prospective randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2021. PMID: 33931900. doi:10.1111/jdv.17331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。